Skip to content

Phenotype/Genotype Correlations in Movement Disorders

Phenotype/Genotype Correlations in Movement Disorders

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00018889
Enrollment
2500
Registered
2001-07-09
Start date
2001-10-22
Completion date
Unknown
Last updated
2026-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Movement Disorder

Keywords

Clinical Evaluation, Genetic Study, Essential Tremor, Familial Myoclonus, Hereditary Ataxia, Natural History, Movement Disorder, Inherited Movement Disorder

Brief summary

The goal of this protocol is to identify families with inherited movement disorders and evaluate disease manifestations to establish an accurate clinical diagnosis by using newest technological advances and investigate the underlying molecular mechanisms. Studies of inherited movement disorders in large families with good genealogical records are especially valuable. Patients with diseases of known molecular basis will be genotyped in order to investigate phenotype/genotype correlation. Patients with disease of unknown or incomplete genetic characterization will be studied with a hope of contributing to the identification of specific disease-causing genes and genetic mechanisms responsible for a specific disorder.

Detailed description

Objective: The primary objective of this study is to perform phenotypic and genotypic characterizations of patients and family members with a known or suspected diagnosis of a movement disorder and screen for eligibility to participate in other movement disorder related protocols: * 14-N-0086 Deep brain stimulation therapy in movement disorders * 11-N-0211 Deep brain stimulation surgery for movement disorders * 000865: Natural history of movement disorders * 00-N-0043: Clinical and molecular manifestations of inherited neurologic disorders * 03-AG-N-329 (NIA): The genetic characterization of movement disorders and dementias * 20M0082 Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease; Institute (NIMH) The secondary goals of this protocol are to learn more about genetic causes of movement disorders and their phenotypic associations; identify patients and families with inherited movement disorders; evaluate disease manifestations to establish an accurate clinical diagnosis; and to investigate the underlying molecular mechanisms. Studies of inherited movement disorders in large families with well-documented genealogical records are especially valuable. The study will also assess a series of exploratory peripheral biomarkers, including, but not limited to, those delineated by DNA, RNA, protein, and/or metabolite alterations in an effort to more accurately predict those with, or at risk of having, the specific neurological disease. Study population: Subjects older than 2 years old with movement disorders and their family members will be enrolled. Patients with diseases of known molecular basis will be genotyped in order to investigate phenotype/genotype correlations. Patients with disease of unknown or incomplete genetic characterization will be studied with a hope of contributing to the identification of specific disease-causing genes and genetic mechanisms and/or peripheral bio-signatures involved in a particular disorder. Design: This is an observational diagnostic study of movement disorders and their progression and pathophysiology. Outcome measures: Determination of phenotype/genotype correlations in specific movement disorders, referral of patients and/or family members for participation in other NIH studies, gene identification if not known, gene expression and protein, metabolite and nucleic acid levels, collection of blood cells and generation of induced pluripotent stem cell lines, and establishment of a clinical diagnosis when possible.

Interventions

None listed

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)
Lead SponsorNIH

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* INCLUSION CRITERIA: * Individuals with suspected movement disorders * Family members of movement disorders patients * Ability to give informed consent or have a legally authorized representative able to give consent (for adults without consent capacity) or parent/guardian able to provide informed consent (for a child) * If unable to give informed consent, ability to give assent (for children or adults without consent capacity) * NIH Employees can participate in this study if they meet eligibility.

Exclusion criteria

* Pregnant women * Children less than 2 years of age * Employees of the Parkinson's Disease Clinic, NINDS

Design outcomes

Primary

MeasureTime frameDescription
The primary outcome measure is the phenotypic and genotypic characterizations of patients and family members with movement disorders.10 YearsCharacterizations to determine their eligibility for inclusion in other NIH protocols.

Secondary

MeasureTime frame
Identification of disease-specific biomarkers in stem cells derived from patient peripheral blood mononuclear cells or fibroblast linesStudy end
Identification of new genes and/or peripheral blood biomarkers associated with movement disordersStudy end
Identification of new genes and/or peripheral blood biomarkers associated with movement disorders.Study end
Establishment of a clinical diagnosis (when possible)Study end
Referral of patients and/or family members for participation in other NIH studiesStudy end

Countries

United States

Contacts

CONTACTKonjit Yirgashewa
konjit.yirgashewa@nih.gov(301) 594-5277
CONTACTDebra J Ehrlich, M.D.
debra.ehrlich@nih.gov(301) 443-7888
PRINCIPAL_INVESTIGATORDebra J Ehrlich, M.D.

National Institute of Neurological Disorders and Stroke (NINDS)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 19, 2026